Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients

Authors: Jian-Wei Xie, Jun Lu, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ze-Ning Huang, Ju-Li Lin, Chao-Hui Zheng, Ping Li, Chang-Ming Huang

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

To assess the prognostic factors and investigate the optimal treatment of gastric mixed adenoneuroendocrine tumors.

Methods

We retrospectively analyzed clinical data from 80 patients with gastric mixed adenoneuroendocrine carcinoma that received radical resection in our department from January 2007 to December 2016. Risk factors for relapse and survival were analyzed using a multivariate Cox proportional hazards regression model. Gastric mixed adenoneuroendocrine carcinoma was divided into neuroendocrine carcinoma and adenocarcinoma based on the predominant type in the tumor.

Results

The 3-year overall survival was 40% in the neuroendocrine carcinoma group and 75% in the adenocarcinoma group (P = 0.006). The neuroendocrine carcinoma (NEC)-dominant tumors and a Ki-67-positive index ≥60% were independent risk factors for worse overall survival. The 3-year recurrence-free survival was 33% in the neuroendocrine carcinoma group and 68% in the adenocarcinoma group. NEC-dominant tumors and a Ki-67-positive index ≥60% were independent risk factors for gastric mixed adenoneuroendocrine carcinoma recurrence. Patients in the adenocarcinoma group that received adjuvant chemotherapy exhibited significantly better overall survival than patients that did not receive chemotherapy (median survival time 43 months vs. 13 months, P = 0.026).

Conclusion

The NEC-dominant tumors and a Ki-67-positive index ≥60% were significantly associated with worse survival and a higher recurrence rate for gastric mixed adenoneuroendocrine carcinoma patients. Patients in the adenocarcinoma group may benefit from gastric adenocarcinoma treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–72.CrossRef Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12(2):153–72.CrossRef
2.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRef
3.
go back to reference Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef
4.
go back to reference Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 13–4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 13–4.
5.
go back to reference Tanaka T, Kaneko M, Nozawa H, Emoto S, Murono K, Otani K, et al. Diagnosis, assessment, and therapeutic strategy for colorectal mixed Adenoneuroendocrine carcinoma. Neuroendocrinology. 2017;105(4):426–34.CrossRef Tanaka T, Kaneko M, Nozawa H, Emoto S, Murono K, Otani K, et al. Diagnosis, assessment, and therapeutic strategy for colorectal mixed Adenoneuroendocrine carcinoma. Neuroendocrinology. 2017;105(4):426–34.CrossRef
6.
go back to reference Pastorello RG, de Macedo MP, da Costa Junior WL, Begnami MDFS. Gastric pouch mixed Adenoneuroendocrine carcinoma with a mixed adenocarcinoma component after roux-en-Y gastric bypass. J Investig Med High Impact Case Rep. 2017;5(4):2324709617740908.PubMedPubMedCentral Pastorello RG, de Macedo MP, da Costa Junior WL, Begnami MDFS. Gastric pouch mixed Adenoneuroendocrine carcinoma with a mixed adenocarcinoma component after roux-en-Y gastric bypass. J Investig Med High Impact Case Rep. 2017;5(4):2324709617740908.PubMedPubMedCentral
7.
go back to reference Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37(7):949–59.CrossRef Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37(7):949–59.CrossRef
8.
go back to reference La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373–84.CrossRef La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42(10):1373–84.CrossRef
9.
go back to reference Kim DH, Kim SM, Hyun JK, Choi MG, Noh JH, Sohn TS, et al. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods. Ann Surg Oncol. 2013;20(7):2317–27.CrossRef Kim DH, Kim SM, Hyun JK, Choi MG, Noh JH, Sohn TS, et al. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods. Ann Surg Oncol. 2013;20(7):2317–27.CrossRef
10.
go back to reference Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117(20):4617–22.CrossRef Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117(20):4617–22.CrossRef
11.
go back to reference Japanese Gastric Cancer A. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer. 1998;1(1):0–24. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma - 2nd English edition. Gastric Cancer. 1998;1(1):0–24.
12.
go back to reference Domori K, Nishikura K, Ajioka Y, Aoyagi Y. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis. Gastric Cancer. 2014;17(2):263–72.CrossRef Domori K, Nishikura K, Ajioka Y, Aoyagi Y. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis. Gastric Cancer. 2014;17(2):263–72.CrossRef
13.
go back to reference Furlan D, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S, et al. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Investig. 2003;83(7):963–71.CrossRef Furlan D, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S, et al. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Investig. 2003;83(7):963–71.CrossRef
14.
go back to reference Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987;11:71–86.CrossRef Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987;11:71–86.CrossRef
15.
go back to reference Xie JW, Lu J, Lin JX, Zheng CH, Li P, Wang JB, et al. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget. 2017;8(34):57495–504.CrossRef Xie JW, Lu J, Lin JX, Zheng CH, Li P, Wang JB, et al. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget. 2017;8(34):57495–504.CrossRef
16.
go back to reference Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, et al. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol. 2012;5(2):313–9.CrossRef Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, et al. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol. 2012;5(2):313–9.CrossRef
17.
go back to reference Kim TY, Chae HD. Composite neuroendocrine carcinoma with adenocarcinoma of the stomach misdiagnosed as a giant submucosal tumor. J Gastric Cancer. 2011;11(2):126–30.CrossRef Kim TY, Chae HD. Composite neuroendocrine carcinoma with adenocarcinoma of the stomach misdiagnosed as a giant submucosal tumor. J Gastric Cancer. 2011;11(2):126–30.CrossRef
18.
go back to reference Fernandes D, Soares JB, Rolanda C. Gastric mixed Adenoneuroendocrine carcinoma. GE Port J Gastroenterol. 2015;22(1):34–6.CrossRef Fernandes D, Soares JB, Rolanda C. Gastric mixed Adenoneuroendocrine carcinoma. GE Port J Gastroenterol. 2015;22(1):34–6.CrossRef
19.
go back to reference Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, et al. High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. J Chin Med Assoc. 2015;78(8):454–9.CrossRef Chen MH, Kuo YJ, Yeh YC, Lin YC, Tzeng CH, Liu CY, et al. High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. J Chin Med Assoc. 2015;78(8):454–9.CrossRef
20.
go back to reference Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–70.CrossRef Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–70.CrossRef
21.
go back to reference Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, et al. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol. 2017;23(3):516–24.CrossRef Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, et al. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol. 2017;23(3):516–24.CrossRef
22.
go back to reference Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14(2):161–5.CrossRef Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14(2):161–5.CrossRef
Metadata
Title
Prognostic factors for survival after curative resection of gastric mixed adenoneuroendocrine carcinoma: a series of 80 patients
Authors
Jian-Wei Xie
Jun Lu
Jia-Bin Wang
Jian-Xian Lin
Qi-Yue Chen
Long-Long Cao
Mi Lin
Ru-Hong Tu
Ze-Ning Huang
Ju-Li Lin
Chao-Hui Zheng
Ping Li
Chang-Ming Huang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4943-z

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine